All the news Showing 10 of 59 articles from: Antiviral therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources WHO issues its first hepatitis B treatment guidelines World Health Organization / 12 March 2015 Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients Liz Highleyman / 05 February 2015 People with chronic hepatitis B virus (HBV) infection are more likely to experience favourable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir – ... Entecavir and tenofovir work well for people with drug-resistant hepatitis B virus Liz Highleyman / 04 February 2015 A combination of entecavir plus tenofovir effectively suppressed hepatitis B virus (HBV) in people with resistance to other antivirals, according to results from the European ENTEBE study presented at the American Association for ... FDA places Arrowhead Hepatitis B drug on partial hold, shares plunge Reuters / 13 January 2015 Tekmira Pharmaceuticals and OnCore Biopharma Announce Merger Agreement to Create Leading Global Hepatitis B Virus Company Tekmira press release / 13 January 2015 Tenofovir continues to suppress hepatitis B virus for eight years Keith Alcorn / 05 December 2014 Most people with chronic hepatitis B who are treated with tenofovir for eight years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver ... Entecavir + tenofovir works well for people with hepatitis B who have had prior treatment failure Liz Highleyman / 28 November 2013 A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated among people with chronic hepatitis B who had experienced treatment failure with ... Hepatitis B treatment with entecavir or tenofovir lowers, but does not eliminate, liver cancer risk Liz Highleyman / 11 November 2013 Long-term treatment with entecavir can reduce the likelihood that people with chronic hepatitis B will develop hepatocellular carcinoma, according to findings presented last week at The Liver Meeting 2013, the 64th annual meeting ... Entecavir and tenofovir both work well against hepatitis B in clinical practice Liz Highleyman / 25 October 2013 Entecavir (Baraclude) and tenofovir (Viread) both demonstrated potent activity against hepatitis B virus (HBV) in a Turkish study presented at the IDWeek 2013 conference held recently in San Francisco. Entecavir appeared to have an ... Medivir and Daewoong pull plug on hepatitis B drug PharmaTimes / 06 September 2013 ← Prev1...23456Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E NAFLD Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds